Press Releases

Takeda and Arbor enter into a license, development and commercialization agreement for EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Deerfield, Ill., Osaka, Japan, and Atlanta, September 12, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC (“Arbor”) announced today that Takeda…

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Nymalize™ (nimodipine) oral solution. Nymalize was previously granted Orphan designation which provides seven years of market exclusivity. Nymalize is the first and only nimodipine oral solution indicated for the improvement of neurological outcome…

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for Gliadel® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc.